Collaboration on EU-Funded Biomarker Cancer Study

(San Jose, CA, USA) is one of three commercial partners accepted as a collaborator in the DISMAL (Molecular Signatures as Diagnostic and Therapeutic Targets for Disseminated Epithelial Malignancies) project, a European-based, three-year biomarker study directed toward the detection and dissemination of tumor cells.

The venture was organized and funded by the European Union (EU), and is comprised of 11 academic research centers and three commercial partners with long-term expertise in micro-metastasis research and is being led by Dr. Klaus Pantel, professor at the University Medical Center Hamburg-Eppendorf (Germany).

In its role in the DISMAL-project, Applied Imaging will develop scanning hardware and software for the rapid and accurate detection of disseminated tumor cells (DTCs) based on its Ariol platform's rare cell detection and analysis capabilities. The project includes developments for improved DTC detection utilizing high-speed image processing technology, as well as the development of detection algorithms and data transfer software.

Commenting on the agreement, Robin Stracey, president and CEO of Applied Imaging, said "We are pleased to be the only imaging company collaborating on this high profile study into the detection and characterization of tumor cells. We expect our work on the DISMAL-project will be incorporated into the circulating tumor cell [CTC] system we are developing and will further enhance the presence of our Ariol systems in cancer research and diagnostics in the European market.”

Applied Imaging is a supplier of automated imaging and image analysis systems for the detection and characterization of chromosomes and molecular markers in genetics and pathology applications. The company develops, manufactures, and markets a range of scanning and image analysis systems for both traditional (brightfield) and fluorescent microscopic analysis of cellular and tissue specimens.



Related Links:
Applied Imaging